601607 上海医药
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入147,469,7294.15%283,579,601275,250,935260,295,089231,981,300
减:营业总成本142,616,5353.64%276,283,477267,676,307253,008,864224,907,251
    其中:营业成本131,209,4373.59%253,163,121244,619,261228,966,947201,494,923
               财务费用694,509-7.37%1,407,2241,480,9121,485,7581,313,192
               资产减值损失(28,045)-93.16%(1,018,556)(614,374)(561,277)(331,471)
公允价值变动收益1,951-97.42%332,121203,854404,731218,738
投资收益827,279-74.60%3,170,144380,427(68,123)533,117
    其中:对联营企业和合营企业的投资收益48,792-87.18%284,473521,909129,329526,743
营业利润5,639,763-17.47%9,942,0868,140,7137,667,2359,014,650
利润总额5,631,383-17.44%9,819,8058,020,0077,054,2978,808,353
减:所得税费用1,289,727-29.37%2,846,0872,149,9951,887,7261,816,339
净利润4,341,656-13.08%6,973,7185,870,0115,166,5706,992,015
减:非控股权益837,20956.22%1,249,1601,317,4831,398,5711,374,863
股东净利润3,504,447-21.40%5,724,5584,552,5283,768,0005,617,152

市场价值指针
每股收益 (元) *0.950-20.83%1.5401.2301.0201.610
每股派息 (元) *0.100-16.67%0.4700.3700.4100.610
每股净资产 (元) *21.1274.33%20.46519.33018.50018.137
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容